Your trusted source for investing success

Tag: FDA

National Research Council and Lexaria Bioscience Commence Laboratory Work

National Research Council and Lexaria Bioscience Commence Laboratory Work

Lexaria Bioscience Corporation (CSE:LXX,OTCQB:LXRP) announces the start of laboratory work under its collaborative research program with the National Research Council of Canada (“NRC”), following the completion of preparation initiatives announced on March 14, 2017.

As earlier reported, several studies will be initiated in the coming months designed to optimize Lexaria’s patented technology

Lexaria Bioscience Awarded Australian Patent For Cannabinoid Infused Edibles

Lexaria Bioscience Awarded Australian Patent For Cannabinoid Infused Edibles

Lexaria Bioscience Corporation (CSE:LXX,OTCQB:LXRP) is pleased to announce that the Australian Patent Office has granted patent #2015274698 which protects Lexaria’s method of improving absorption, speed of onset, and taste of cannabinoid active agents in edible products. The term of the patent is 20 years from June 10, 2015.

The issuance of this

DelMar Pharmaceuticals Announces Completion of First Site Initiation Visit for STAR-3 Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM

DelMar Pharmaceuticals Announces Completion of First Site Initiation Visit for STAR-3 Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced the completion of the first site initiation visit at the Dent Neurological Institute (“Dent”) for its pivotal Phase 3 Study in Temozolomide-Avastin (bevacizumab) Recurrent GBM (“STAR-3”).  Site initiation visits are generally the final step before patient enrollment.

The

5 Top Biotech Stocks on the TSX Year-to-date

5 Top Biotech Stocks on the TSX Year-to-date

The biotech sector has steadily enjoyed an increase this year, in part thanks to significant advancements and in spite of the uncertainty from the White House as the proposal of a new healthcare bill holds the grip of most life science markets.

Q BioMed Inc : SeeThruEquity Issues Update on Q BioMed Inc. (QBIO)

Q BioMed Inc : SeeThruEquity Issues Update on Q BioMed Inc. (QBIO)

SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Q BioMed Inc. (OTCQB:QBIO).

Q BioMed Inc. (OTCQB: QBIO) is a biomedical acceleration and development company focused on identifying, acquiring and licensing attractive biomedical assets from small

Enter Your Log In Credentials
×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network